Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa

研究成果: Article同行評審

3 引文 斯高帕斯(Scopus)

摘要

Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse. Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months. Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

原文English
文章編號e11053
期刊Medicine (United States)
97
發行號25
DOIs
出版狀態Published - 2018 六月 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

指紋 深入研究「Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa」主題。共同形成了獨特的指紋。

引用此